LLY - ELI LILLY & Co
884.54
24.810 2.805%
Share volume: 3,383,477
Last Updated: 04-25-2025
Pharmaceutical Products/Pharmaceutical Preparations:
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$859.73
24.81
0.03%
Fundamental analysis
69%
Profitability
75%
Dept financing
25%
Liquidity
54%
Performance
77%
Performance
5 Days
8.13%
1 Month
6.99%
3 Months
9.45%
6 Months
-1.23%
1 Year
20.59%
2 Year
135.08%
Key data
Stock price
$884.54
DAY RANGE
$851.07 - $885.58
52 WEEK RANGE
$677.09 - $972.53
52 WEEK CHANGE
$19.99
DIVIDEND
$1.50
EX-DIVIDEND DATE
02-14-2025
NEXT EARNINGS DATE
05-01-2025
Company detail
CEO: David A. Ricks
Region: US
Website: lilly.com
Employees: 39,000
IPO year: 1972
Issue type: Common Stock
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Region: US
Website: lilly.com
Employees: 39,000
IPO year: 1972
Issue type: Common Stock
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic colorectal cancer, and hepatocellular carcinoma. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic ax
Recent news
